ArticleDigestive diseases and sciences2025
Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeResmetirom, a liver-targeted thyroid hormone receptor-β (THR-β) agonist, used to treat MASH, shares a similar mechanism of action with levothyroxine, a nonselective (THR-α/β) receptor agonist used to treat hypothyroidism. Given the potential effect of levothyroxine on THR-β, we hypothesized that it may have beneficial effects in MASH patients.
methodsWe used TriNetX to examine patients aged ≥ 18 years with MASH treated with levothyroxine from 1/1/16 to 1/1/25. Patients prescribed levothyroxine (levothyroxine group) were compared to those not receiving them (control group). Patients with previous cirrhosis or liver transplant were excluded. To control for disease severity and underlying comorbidities, propensity score matching (PSM) was performed.
resultsOf 109,268 patients with MASH, 17,629 (16%) received levothyroxine. Following PSM, we examined 15,076 patients in each group. MASH patients with or without levothyroxine treatment were predominantly White females, with a mean [SD] bilirubin, INR, and creatinine of 0.6 [0.7], 1.1 [0.4], and 0.9 [1.2], respectively. Comorbidities, BMIs, and MASH therapies including GLP-1s, SGLT-2s, and statins were similar in both groups. Over a mean [SD] follow-up of 2.8 [1.8] years, patients receiving levothyroxine had a similar rate of progression to cirrhosis (HR: 1.08; 95% CI 0.97-1.21; p = 0.16) as patients not on levothyroxine. In patients who developed cirrhosis, those receiving levothyroxine had a small, but statistically significantly higher risk of developing any portal hypertensive complication (HR: 1.33; 95% CI 1.18-1.49; p < 0.001) than those not receiving levothyroxine.
conclusionMASH patients prescribed levothyroxine had a similar rate of progression to cirrhosis and a slightly higher rate of portal hypertension complications than those not prescribed levothyroxine.
Indexed as
Identifiers
40884700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.